Epigenome-wide study uncovers large-scale changes in histone acetylation driven by tau pathology in aging and Alzheimer's human brains

• Main Authors: Klein, Hans-Ulrich (Author), McCabe, Cristin (Author), Gjoneska, Elizabeta (Author), Sullivan, Sarah E (Author), Kaskow, Belinda J (Author), Tang, Anna (Author), Smith, Robert V (Author), Xu, Jishu (Author), Pfenning, Andreas R (Author), Bernstein, Bradley E (Author), Meissner, Alexander (Author), Schneider, Julie A (Author), Mostafavi, Sara (Author), Tsai, Li-Huei (Author), Young-Pearse, Tracy L (Author), Bennett, David A (Author), De Jager, Philip L (Author)
• Format: Article
• Language: English
• Published: Springer Nature, 2021-12-06T19:49:21Z.
• Subjects: Article
• Online Access: Get fulltext

© 2018, The Author(s), under exclusive licence to Springer Nature America, Inc. Accumulation of tau and amyloid-β are two pathologic hallmarks of Alzheimer's disease. We conducted an epigenome-wide association study using the histone 3 lysine 9 acetylation (H3K9ac) mark in 669 aged human prefrontal cortices; in contrast with amyloid-β, tau protein burden had a broad effect on the epigenome, affecting 5,990 of 26,384 H3K9ac domains. Tau-related alterations aggregated in large genomic segments reflecting spatial chromatin organization, and the magnitude of these effects correlated with the segment's nuclear lamina association. Functional relevance of these chromatin changes was demonstrated by (1) consistent transcriptional changes in three independent datasets and (2) similar findings in two mouse models of Alzheimer's disease. Finally, we found that tau overexpression in induced pluripotent stem cell-derived neurons altered chromatin structure and that these effects could be blocked by a small molecule predicted to reverse the tau effect. Thus, we report broad tau-driven chromatin rearrangements in the aging human brain that may be reversible with heat-shock protein 90 (Hsp90) inhibitors.